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Abstract Pathogenic mutations in CYLD can be identi-
fied in patients affected with Brooke-Spiegler syndrome,
(Familial) Cylindromatosis or multiple familial trichoepi-
thelioma. To date, only technologies which are able to
identify small point mutations in CYLD, such as sequence
and WAVE analysis, were used. Here we describe the
identification of a larger rearrangement identified by
Quantitative PCR analysis of CYLD, indicating that a
combination of these technologies is necessary when
searching for pathogenic mutations in CYLD.
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rearrangement  Mutation analysis  Q-PCR analysis
Introduction
Brooke-Spiegler syndrome (BSS; OMIM #60541) is an
autosomal dominant disorder characterised by cylindromas,
trichoepitheliomas and spiradenomas, especially in the head
and neck region. Due to the clinical overlap with (familial)
Cylindromatosis (FC; OMIM #132700) and multiple
Familial Trichoepithelioma (MFT; OMIM #601606), these
disorders are considered to represent a single disease entity
[1–3].
Linkage analysis was used to define the familial cylin-
dromatosis region, resulting in the identification of CYLD
[4–6]. Germline mutations in CYLD have been identified in
BSS, FC and MFT patients, in agreement with the clinical
findings indicating that these disorders have a common
genetic basis [6–11]. CYLD is encoded by 20 exons of
which exon 4 contains the ATG start codon [6]. The CYLD
protein is a deubiquitinating enzyme regulating cell sig-
nalling via several pathways, including the NF-jB and
JNK pathways [12–14].
Recently, a nice overview was published by Blake and
Toro where they described 51 distinct germline mutations
in CYLD in 73 families with BSS, FC and MFT [7]. All
types of mutations were identified: frameshift (41%),
nonsense (35%), missense (14%) and putative splice site
(10%). No large rearrangements were identified, probably
because all techniques used were not suitable for identi-
fying this type of mutation. Loss of heterozygosity is
shown in cylindromas and trichoepitheliomas, indicating
that CYLD acts as a tumour suppressor gene [6, 8, 15–17].
This observation is in agreement with the function of the
CYLD protein in regulating several pathways in cell sig-
nalling. In most tumour suppressor genes, e.g. BRCA1,
NF1, TSC2, large rearrangements are identified as patho-
genic germline mutations [18–20]. Therefore we hypothe-
sized that larger rearrangements in CYLD could be
identified in patients with BSS, FC and MFT.
Here we describe the identification of a large rear-
rangement in CYLD in a patient with FC using Quantitative
(Q)-PCR, indicating that a quantitative test should be
performed on DNA samples of patients if no mutation was
identified by techniques which can only identify small
sequence changes, such as sequence or WAVE analysis.
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Materials and methods
Patient samples
In our diagnostic setting we received 13 samples from
patients with Brooke-Spiegler syndrome (BSS, n = 2),
(Familial) Cylindromatosis [(F)C; n = 7] or Trichoepi-
thelioma (T; n = 2). Of the remaining two patients the
indication for testing CYLD was not provided by the
applicant (Table 1). Clinical details were obtained only
from the patient described in this paper.
Mutation analysis
Extraction of DNA from peripheral blood cells was per-
formed according to standard techniques. Mutation analy-
sis of the coding exons 4–20 and exon/intron boundaries of
CYLD was performed by sequence analysis (primers
available on request) using an automated sequencer (ABI
3730XL, Applied Biosystems, Foster City, CA, USA).
Data were analysed using SeqScape software (version 2.6;
Applied Biosystems). If a sequence change could not be
classified as a pathogenic mutation, the sequence change
was analysed using Alamut software (Mutation Interpre-
tation Software; version 1.5 May 2009; Interactive Bio-
software, Rouen, France).
In case no pathogenic mutation or an unclassified variant
was identified, Quantitative (Q)-PCR analysis was per-
formed to search for large rearrangements.
Quantitative-PCR, Long-range-PCR and sequence
analysis of breakpoints
Real-time Q-PCR was performed using Fam-labelled Taq-
man assays. Oligonucleotides were designed for all (non)
coding exons. If the CG content was too high (exon 1) or too
low (exons 14–17), a Taqman assay was designed using
oligonucleotides in the promoter region (instead of exon 1)
and in the intronic regions between exons 14 and 17 as close
as possible to the exons (Table 2). Oligonucleotides were
designed with Primer Express 2.0.0 (Applied Biosystems).
Primer specificity was checked by performing BLAST
analysis. Taqman probes were synthesised with a melting
temperature (Tm) 8–10C higher than the primers by incor-
porating Locked Nucleic Acid (LNA) monomers in the
probe. Tm values for the LNA probes were calculated using
the Exiqon website (http://lna-tm.com/). The LNA-based
Taqman assays were manufactured by Eurogentec (Maas-
tricht, The Netherlands). Since LNA probes show a high
thermal stability and are resistant to exo- and endonuclease
activity [21], we prefer the use of these probes in the Taqman
assay.
Gene dosage alterations were detected on an ABI7500
Real time PCR system (Applied Biosystems) by perform-
ing a relative quantification run. Real time PCR reactions
were performed in a total volume of 25 ll, containing
20 ng DNA, 1 9 qPCR mastermix Plus–low ROX (Euro-
gentec: RT-QP2x-03-WOULR), 1 9 RNAse P (endoge-
nous control; Applied Biosystems), 30 lM forward and
reverse primers and 10 lM probe. PCR conditions were as
follows: an initial 2 min incubation at 50C, followed by
95C for 10 min and then 40 cycles of 95C for 15 s and
60C for 1 min. All samples were analysed in triplicate and
compared to a normal control sample.
LR-PCR was performed with the Expand Long Template
PCR System (Roche Applied Science, Indianapolis, IN,
USA). The product obtained by LR-PCR was sequenced
using an automated sequencer (ABI 3730XL). Nomencla-
ture of the deletion was according to the recommendations
of the Human Genome Variation Society, using reference
sequence NM_015247_2. After characterisation of the
breakpoints in patient 37999, a deletion-specific PCR
Table 1 Overview of patients
analysed for mutations in CYLD
BSS Brooke-Spiegler syndrome
C Cylindromatosis
FC Familial cylindromatosis
ND No data
T Trichoepithelioma
* Unclassified variant
ID number Gender Indication Mutation Exon
41356 F ND c.1112C[A p.Ser371X 9
14872 F T c.1682T[A p.Leu561X 11
17514 F C c.2065_2066delCT p.Leu689fs 15
17559 F FC c.2068_2069delTTinsC p.Phe690fs 15
35680 F C c.2146C[A* p.Gln716K 16
22748 F C c.2272C T p.Arg758X 17
41440 F BSS c.2350?5G[A* p.? 17
42008 F FC c.2655G[A p.Trp885X 19
11468 F FC c.2662_2664delTTT* p.Phe888del 19
37999 F FC c.2686?60_*3340del5362 p.? 20
28597 F BSS normaal
30945 F T normaal
32565 M ND normaal
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analysis was designed. Three primers (Table 2) were used:
a common primer, a primer specific for the deletion and a
primer specific for the wildtype allele. The primers were
designed in such a way that the PCR product from the allele
carrying the deletion was shorter than the product from the
wildtype allele. The PCR conditions were: an initial 2 min
incubation at 94C, followed by 30 cycles of 94C for 60 s,
60C for 30 s and 72C for 90 s and completed by 72C for
10 min.
Results
Mutation analysis
Using sequence analysis of all coding exons and exon
intron boundaries of CYLD, a pathogenic mutation was
identified in 6 out of 13 patients of our diagnostic cohort
(Table 1). Of these mutations, c.1112C[A (p.Ser371X)
and c.2272C[T (p.Arg758X) were previously described.
The c.2272C[T (p.Arg758X) mutation was found in two
families with different haplotypes, indicating that this
mutation is a recurrent mutation in CYLD [6]. In three
patients, an unclassified variant was identified: c.2146C[A
(p.Gln716K), c.2350?5G[A and c.2662_2664delTTT.
One of these variants, c.2350?5G[A was previously
described, but no formal proof that this sequence change is
a pathogenic mutation was provided [6]. Three splice site
Table 2 Overview of oligonucleotides used for Q-PCR analysis and
deletion-specific breakpoint PCR
Location Taqman oligonucleotides cDNA numbering 50–30
Promoter ggctcagcgtggttgtgact c.-415 - 516
tctttggcgctttcattcagt c.-415 - 458
cctcapgtcacgcagc c.-415 - 495
Exon 2 tttctagggtgaggatggttctaca c.-332
agggcgcacctttcaactaag c.-271
agclaclcgpagtt c.-306
Intron 3 tgtcttactgttccctaggccttt c.-124 ? 398
cccaacatcaatccacattcac c.-124 ? 462
cttaaapglapaapctg c.-124 ? 423
Exon 4 cgtgggctgtcctgtgaaa c.378
agcgtacaactccaggaaattttt c.442
tacegltpapatltgg c.398
Exon 5 ggagaaacaatagaatctggaacagtt c.721
ccacaccaacaaaatatcctaagct c.802
tgtgatpttttglcapgaa c.754
Exon 6 ggcaactgggatggaagatt c.820
ttgtactttcaacacacgcaaaact c.883
atgpaptpceglttt c.842
Exon 7 ctcaaatccactgtgggtgatatc c.914 - 42
tccaacacgacacttaggagtca c.922 ? 26
tttttpctgalacalagc c.914 - 17
Exon 8 agagtgtgacgcaggaaagga c.923
tgtccccaacacctcttgaca c.985
cctcclaaalttpcctt c.946
Intron 9 tgtgcagtgaaggtgcatga c.1138 ? 537
cccctaagaccctgagaaaaatc c.1138 ? 602
ctgtpapaatalaclaaag c.1138 ? 559
Exon 10 tggccacagtccactttctct c.1299
cgggtgcagtgtttagctctt c.1360
tcapcclagtltptaatg c.1321
Exon 11 gctgtacggatggaaccttca c.1535
cacaaacagcgccttcttca c.1602
tcggtatttlalctgtgcc c.1563
Exon 12 cttggagataatgattgggaagaag c.1749
gaataaggttgagtctaagtaacaagaattgt c.1824
aagglatclagpgtc c.1775
Exon 13 tcttttgcagcttatttgcttttagt c.1827 - 10
catcgttcttttctttgggtctaagt c.1888
ctgttltpgacaltgtg c.1844
Intron 14 aaagattcaccacctgactttgaat c.2042 - 399
ttcctgcaagcctctgaacatt c.2042 - 326
tgtlapcaglataltgta c.2042 - 373
Intron 15 agcgccttcattttagaaatgaa c.2109 - 456
tgctggatgtgacagaccctta c.2109 - 390
agttlgazctapaapgtc c.2109 - 432
Intron 16 tcaagattattgaactctgtgacctctag c.2242 - 243
caagtcttcaagtggctcatgatc c.2242 - 173
tgctpgtgtpcccc c.2242 - 213
Table 2 continued
Location Taqman oligonucleotides cDNA numbering 50–30
Exon 18 ctcacatttcagctcccagaca c.2351 - 12
gcattctctacactcatacattgcaa c.2406
tgccgpatatgtpgagg c.2362
Exon 19 cccagtgtcacttcccaaaga c.2508
aagggatgcagccgtgtct c.2566
ttacclgactpggactg c.2530
Exon 20 aagatgtctctggaagacctgcat c.2749
ttcgtgcacagccttgga c.2809
ccttpgactccapgaga c.2774
Primers for deletion PCR
c.2686?60_*3340del5362
Forward cccagtgtcacttcccaaaga c.2508
Reversed tcgtccctactctgccactt c.*3563
Internal cctcaagccccttaaacctc c.2686 ? 715
cDNA numbering is according to reference sequence NM_015247_2.
In the oligonucleotides used in the Taqman assay, the following
abbreviations are used for the LNA incorporations: E, A-LNA; L,
C-LNA; P, G-LNA and Z, T-LNA
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prediction programs of Alamut (SpliceSiteFinder-like,
MaxEntScan and NNSPLICE) showed that it is very likely
that the sequence change c.2350?5G[A will have an
effect on RNA splicing (data not shown). The fourth pro-
gram, GeneSplicer, did not recognise the wildtype donor
site and therefore no conclusion could be drawn from this
program. Since we did not receive relevant family mem-
bers to analyse the presence/absence of c.2350?5G[A, or
a new sample of the index patient to perform RNA anal-
ysis, we were not able to prove that c.2350?5G[A is a
pathogenic splice site mutation. No DNA of relevant rel-
atives of the patients with the unclassified variants
c.2146C[A (p.Gln716K) and c.2662_2664delTTT was
received to obtain further information with respect to the
pathogenic character of these sequence changes.
No pathogenic mutation or unclassified variant was
identified in four patients.
Identification and characterisation of the large
rearrangement
To identify larger rearrangements, a quantitative technique
must be applied. We developed Q-PCR analyses for all
exons/introns of CYLD and DNA of all patients without a
pathogenic mutation, including the patients carrying an
unclassified variant, was analysed. Q-PCR analysis of
DNA of patient 37999 showed a pattern in agreement with
a deletion of exon 20 (Fig. 1). No abnormal patterns were
identified in DNA of the other 6 patients, indicating that no
large rearrangements are present in these patients (data of
the other exons: not shown).
To characterise the breakpoints, LR-PCR was performed
and the PCR product was sequenced. The deletion started 60
nucleotides after exon 19 and extended 3340 nucleotides after
the translation stopcodon of CYLD. In total 5362 nucleotides
were deleted (c.2686?60_*3340del5362; Fig. 2a and 2b).
No (direct) repeat structures were present in the vicinity of the
breakpoint which could explain the nature of the deletion.
A deletion-specific PCR was developed, showing not only the
wildtype allele of 913 basepairs, but also the mutant specific
fragment of 462 basepairs (Fig. 2c). This analysis confirmed
the presence of the pathogenic mutation in two independent
DNA samples of the patient and can be used for further family
analysis.
Clinical details of patient 37999
The patient, a 47-year old female, was referred because of
the presence of multiple lenticular, smooth papules on the
forehead and the scalp (Fig. 3). The lesions were reported
to be present for 10–15 years. Similar lesions were
Fig. 1 Q-PCR result of exon 20 of patients with no pathogenic
mutation or with an unclassified variant after sequence analysis of
CYLD. Lane 1 no DNA; lane 2 negative control used as calibrator;
lane 3 patient 28597; lane 4 patient 30945; lane 5 patient 32565; lane
6 patient 35680; lane 7 patient 37999; lane 8 patient 41440 and lane 9
patient 11468. Bars represent Relative Quantification (RQ) calculated
by 2- DDCT. On top of the bars, the standard error of the mean RQ
value is displayed. Inside the bars the calculated RQ value is given of
a triplicate measurement
Fig. 2 Characterization of the breakpoint (c.2686?60_*3340del5362)
of patient 37999. a Result of sequence analysis of the long-range PCR
product. The arrow indicates the last nucleotide of intron 19 that is still
present. b Schematic overview of the deletion present in patient 37999.
Exon 19 and the coding part of exon 20 of CYLD are represented by
open boxes and the noncoding part of exon 20 by a black box. The
intergenic region is given by dot with broken line c Agarose gel
electrophoresis of the deletion-specific PCR product. Lane 1 and 2, two
independent DNA samples of patient 37999; lane 3, negative control
DNA and lane 4, no DNA. The wildtype fragment is 913 bp in length
and the mutant fragment 462 bp
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confirmed to be present in her sister, and were reported by
the patient to be present in her father, grandfather and her
son. No other clinical features were present.
Discussion
Our diagnostic cohort of patients with a pathogenic mutation
in CYLD comprised the clinical phenotypes resembling
Brooke-Spiegler syndrome (BSS), (Familial) Cylindroma-
tosis (FC) and (Multiple Familial) Trichoepithelioma
(MFT). One BSS patient was heterozygous for the unclas-
sified variant c.2350?5G[A. This sequence change was
previously described as being a pathogenic mutation, but
there was no formal proof for this conclusion [6]. In silico
analysis showed that the sequence change c.2350?5G[A
might have an effect on RNA splicing and therefore might be
a pathogenic mutation. No pathogenic mutation was identi-
fied in the other BSS patient. Of the seven (F)C patients, five
carried a pathogenic mutation, whereas the two other
patients were carrier of an unclassified variant. In one of two
MFT patients a pathogenic mutation was identified. In one of
the two patients without information with respect to the
indication for testing, a pathogenic mutation could be
identified. Using a combination of sequence and Q-PCR
analyses, 7 pathogenic and 3 unclassified variants in 13
patients (77%) were identified, comparable with the overall
detection rate of 83% previously described [7]. All missense
mutations described to date were located within the USP
(Ubiquitin Specific Protease) domain (amino acids 583–956)
[7, 22]. Therefore it is very likely that the unclassified
variants c.2146C[A (p.Gln716K) and c.2662_2664delTTT
(p.Phe888del) identified in our cohort, were also patho-
genic mutations. In that case, a pathogenic mutation was
identified in all our (F)C patients. This was comparable
with the findings of Saggar et al., who identified pathogenic
mutations in 100% (3/3) and 44% (4/9) of their FC and
MFT patients, respectively, [9]. In agreement with all
previously identified sequence change in CYLD [7], the
localisation of the abnormalities described in this paper
were in exons 9–20. In patient 37999 a large genomic
rearrangement was identified using a quantitative analysis.
This deletion (c.2686?60_*3340del5362) encompassed
almost complete intron 19 and extended in the 30 UTR of
CYLD. If the allele carrying the deletion will lead to a
stable mRNA, the mutant RNA will encode a protein
lacking amino acids 896–956, which are part of the USP
domain (aa 583–956). The mutant CYLD protein will lack
a part of its functional domain and this explains the clinical
phenotype of the patient. The frequency of this type of
rearrangments in CYLD in our cohort is about 10% and is
comparable with the frequencies observed in other genetic
disorders such as Neurofibromatosis type 1 and Tuberous
sclerosis complex [18, 19].
Since there is intra- en interfamilial variability in the
clinical expression, it will be very hard to get a genotype-
phenotype correlation. Our patient with a large rearrange-
ment in CYLD was not severely affected. This might be due
to the fact that the large deletion only encompassed CYLD
and no additional gene(s). It had been suggested that there
is a higher incidence of BSS, (F)C or MFT in females [23],
most likely as a result of reduced penetrance in males [24].
In our cohort, 12 out of 13 patients were females (Table 1),
in agreement with this hypothesis.
To our knowledge, this is the first large germline dele-
tion identified in CYLD, indicating that screening for this
type of mutations in a diagnostic setting is recommended in
patients with Brooke-Spiegler syndrome, (familial) Cylin-
dromatosis or multiple Familial Trichoepithelioma.
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